Redwire Awarded $25 Million Single Award IDIQ Contract by NASA To Provide Biotechnology and Support On-Orbit Operations Aboard the International Space Station

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

08/28/2025 - 07:30 AM

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced it has been awarded a NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract with a $25 million ceiling for a five-year period to fulfill future task orders for biotechnology facilities, on-orbit operations support, mission integration, and related services for the agency on the International Space Station (ISS). Redwire will furnish these services to NASA when and if task orders are issued and there is no limit or minimum on the number of orders that may be issued.

Under this contract, Redwire was recently issued a $2.5 million task order from NASA’s In Space Production Applications (InSPA) program to support additional drug development investigations on the ISS using Redwire’s PIL-BOX technology.

Redwire will provide turnkey services to manage, integrate, and facilitate experiments and support on-orbit operations for NASA-funded research investigations aboard the ISS. Redwire’s capabilities are intended to support the diverse set life and materials sciences research investigations that NASA processes every year.

“Redwire’s biotechnology facilities have been an integral part of NASA’s ISS research strategy, supporting an increased throughput of critical scientific research and expanding on-orbit capabilities to accommodate cutting-edge science in drug development, cancer research, and tissue engineering,” said John Vellinger, President of Redwire In-Space Industries. “As the sole recipient for this IDIQ contract, Redwire is grateful for NASA’s continued trust in our proven biotechnology capabilities and experience, and we are committed to enabling new discoveries for NASA and the ISS science community.”

Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire’s microgravity technology enables space biotechnology and pharmaceutical development, helping companies unlock new insights for potential therapeutics and paving the way for microgravity research on future commercial space stations. Redwire has flown investigations for notable research partners including Bristol Myers Squibb, Eli Lilly and Company, and Butler University. Redwire recently formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals.

About Redwire

Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire’s approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit RDW.com.